SCHEDULE: Goldman Sachs Discloses 2.7% Stake in Intellia Therapeutics

The Goldman Sachs Group and its subsidiary have reported a 2.7% beneficial ownership stake in Intellia Therapeutics, Inc. as of December 31, 2025.

Summary

• The Goldman Sachs Group, Inc. and its subsidiary, Goldman Sachs & Co. LLC, jointly reported beneficial ownership of Intellia Therapeutics, Inc. common stock.
• As of December 31, 2025, the aggregate amount beneficially owned by each reporting person is 3,157,178.33 shares.
• This represents 2.7% of Intellia Therapeutics, Inc.'s class of common stock.
• The reporting persons hold shared voting power over 3,156,786.33 shares and shared dispositive power over 3,156,881.33 shares.
• The securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive signal. The disclosure of a significant institutional stake by Goldman Sachs in Intellia Therapeutics, a company in a high-growth sector, suggests confidence from a major financial player, which can be a positive indicator for other investors.

Positives

• A major institutional investor like Goldman Sachs holding a significant stake can signal confidence in Intellia Therapeutics' long-term prospects.
• The acquisition of shares in the ordinary course of business suggests a strategic investment rather than an activist position.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that a significant stake by a prominent financial institution like Goldman Sachs in a biotechnology company such as Intellia Therapeutics, a leader in CRISPR gene-editing technology, often indicates a belief in the long-term growth potential of the company and the broader gene-editing sector. This type of institutional investment can be viewed positively by the market, suggesting validation of the company's scientific advancements and market position.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional stake by Goldman Sachs could increase investor confidence and potentially lead to positive share price movement.
• Employees: No direct impact mentioned, but increased investor confidence could indirectly support company stability and growth initiatives.
• Customers/Suppliers/Creditors: No direct impact mentioned in this filing.

Key Dates

Recommendation

While the disclosure of a significant stake by Goldman Sachs is a positive signal, a Schedule 13G filing primarily serves as a transparency mechanism for institutional ownership and does not provide new fundamental information about Intellia Therapeutics' operational performance, financial health, or strategic direction. Therefore, a 'hold' recommendation is appropriate, acknowledging the institutional confidence without suggesting immediate action based solely on this ownership disclosure. Investors should consider this alongside Intellia's core business fundamentals and future prospects.

Keywords

Intellia Therapeutics, Goldman Sachs, Schedule 13G, Beneficial Ownership, Common Stock, Biotechnology, CRISPR, Gene Editing, Institutional Investment